Lessons from the withdrawal of rofecoxib.

Dieppe, Paul A; Ebrahim, Shah; Martin, Richard M; Jüni, Peter · BMJ · 2004

editorial · Level V

Where this comes from

Abstract

Patients would be safer if drug companies disclosed adverse events before licensing

Medical subject headings